Brokers name 3 ASX shares to buy today

CSL Limited (ASX:CSL) shares are one of three that brokers have named as buys this week. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

A large number of broker notes have hit the wires this week, leading to many popular shares being declared buys and sells.

Three shares that are in favour with brokers and have been given a buy rating are listed below. Here's why they are bullish on them:

Aristocrat Leisure Limited (ASX: ALL)

According to a note out of Deutsche Bank, its analysts have retained their buy rating and $39.30 price target on this gaming technology company's shares ahead of its half year results release next week. The broker believes that Aristocrat Leisure is winning market share in North America and suspects that its half year result could surprise to the upside. I agree with Deutsche on Aristocrat Leisure and feel its shares offer a compelling risk/reward at the current level.

Costa Group Holdings Ltd (ASX: CGC)

Analysts at UBS have retained their buy rating but trimmed the price target on the horticulture company's shares slightly to $6.70 ahead of its annual general meeting later this month. According to the note, the broker notes that mushroom prices have been weaker and the Moroccan blueberry season has been softer, but it remains confident that Costa will reiterate its earnings growth guidance of +30% at its meeting on May 30. While it may be prudent to wait for its meeting, if its guidance is reiterated then I think Costa's shares are great value at this price.

CSL Limited (ASX: CSL)

Another note out of UBS reveals that its analysts have retained their buy rating and lifted the price target on this global biotech giant's shares to $223.00. According to the note, the broker believes that immunoglobulins growth remains strong and expects Chinese albumin growth to recover. In addition to this, the broker is positive on the prospects of the company's Seqirus influenza vaccines business and expects it to win market share. I agree with UBS and feel CSL would be a great option for investors.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended COSTA GRP FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »